Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation

被引:9
作者
Keil, F
Kalhs, P
Chen, X
Haas, OA
Fritsch, G
Chott, A
Lechner, K
Moser, K
Ackermann, J
Rabitsch, W
Worel, N
Mannhalter, C
Greinix, HT
机构
[1] Univ Vienna, Dept Med 1, Bone Marrow Transplantat Unit, A-1010 Vienna, Austria
[2] St Anna Childrens Hosp, Childrens Canc Res Inst, Vienna, Austria
[3] Univ Vienna, Clin Inst Med & Chem Lab Diagnost, A-1010 Vienna, Austria
[4] Univ Vienna, Clin Inst Pathol, A-1010 Vienna, Austria
[5] Univ Vienna, Dept Transfus Med, A-1010 Vienna, Austria
基金
奥地利科学基金会;
关键词
myeloma; donor leukocyte infusion; chimerism;
D O I
10.1007/s002770050532
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A large group of patients relapsing after allogeneic bone marrow transplantation (BMT) have obtained remission after infusion of leukocytes from their original donor, suggesting a graft-versus-myeloma effect. However, side effects such as graft-versus-host disease and myelosuppression are severe, and sometimes fatal, complications of this therapeutic approach. Previously we demonstrated that patients with leukemia who lack donor hematopoiesis in relapse after BMT experience severe and lasting aplasia after infusion of donor leukocytes. In two patients - one with extramedullary and one with marrow relapse after a sex-mismatched transplantation - we analyzed hematopoietic chimerism by cell sorting and bone marrow cultures. CD34-positive cells, CD4-CD8-positive cells, committed progenitors, and LTC-IC were of donor origin, as demonstrated by two-color fluorescence in situ hybridization (FISH). Additionally, in relapse complete donor T-cell chimerism was seen. In contrast, plasma cells were of recipient origin in the patient who had a relapse in the bone marrow. Both patients were treated with infusions of donor leukocytes from their original donor. Neither patient suffered myelosuppression, and one achieved a stable complete remission.
引用
收藏
页码:376 / 379
页数:4
相关论文
共 24 条
[1]   Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant [J].
Alyea, EP ;
Soiffer, RJ ;
Canning, C ;
Neuberg, D ;
Schlossman, R ;
Pickett, C ;
Collins, H ;
Wang, YL ;
Anderson, KC ;
Ritz, J .
BLOOD, 1998, 91 (10) :3671-3680
[2]  
ARCESE W, 1990, BONE MARROW TRANSPL, V5, P309
[3]   Graft-versus-myeloma effect [J].
Aschan, J ;
Lonnqvist, B ;
Ringden, O ;
Kumlien, G ;
Gahrton, G .
LANCET, 1996, 348 (9023) :346-346
[4]   Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect [J].
Bertz, H ;
Burger, JA ;
Kunzmann, R ;
Mertelsmann, R ;
Finke, J .
LEUKEMIA, 1997, 11 (02) :281-283
[5]  
CAVO M, 1994, INSERM MULH
[6]   Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].
Collins, RH ;
Shpilberg, O ;
Drobyski, WR ;
Porter, DL ;
Giralt, S ;
Champlin, R ;
Goodman, SA ;
Wolff, SN ;
Hu, W ;
Verfaillie, C ;
List, A ;
Dalton, W ;
Ognoskie, N ;
Chetrit, A ;
Antin, JH ;
Nemunaitis, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444
[7]  
COUTINHO LH, 1990, BLOOD, V75, P2118
[8]  
FRITSCH G, 1993, BLOOD, V81, P2301
[9]   PROGNOSTIC FACTORS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MULTIPLE-MYELOMA [J].
GAHRTON, G ;
TURA, S ;
LJUNGMAN, P ;
BLADE, J ;
BRANDT, L ;
CAVO, M ;
FACON, T ;
GRATWOHL, A ;
HAGENBEEK, A ;
JACOBS, P ;
DELAURENZI, A ;
VANLINT, M ;
MICHALLET, M ;
NIKOSKELAINEN, J ;
REIFFERS, J ;
SAMSON, D ;
VERDONCK, L ;
DEWITTE, T ;
VOLIN, L .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1312-1322
[10]   Allogeneic bone marrow transplantation in multiple myeloma [J].
Gahrton, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (02) :251-254